A Pilot Trial of TKI 258 (Dovitinib) in Von Hippel-Lindau Syndrome

Trial Profile

A Pilot Trial of TKI 258 (Dovitinib) in Von Hippel-Lindau Syndrome

Phase of Trial: Phase II

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs Dovitinib (Primary)
  • Indications Haemangioblastoma; Von Hippel-Lindau disease
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Dec 2015 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov record.
    • 23 Mar 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2016, as reported by ClinicalTrials.gov.
    • 01 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top